Moreover, the European Society of Cardiology, in collaboration with the EASD, released updated guidelines for diabetes, prediabetes and heart disease in 2019, recommending SGLT2-is and GLP-1 agonists as first-line therapies for people with diabetes who have heart disease or are at risk of heart disease [111]. Here, GLP1R is linked to heart disorder.